Clinical Trials Update: July 20, 2007
Non-Hodgkin's Lymphoma Hemodialysis Bipolar Disorders
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate the clinical benefits of galiximab when given in combination with rituximab, as compared with rituximab alone in treating follicular non-Hodgkin's lymphoma. Volunteers 18 or older who have relapsed or progressive disease after at least one prior chemotherapy may qualify.
The research sites are located worldwide.
This study will evaluate the effectiveness and safety of the study drug in restoring dysfunctional hemodialysis (HD) catheters. Candidates at least 18 who are using a cuffed tunneled HD catheter and who are not pregnant or breast-feeding may be eligible.
The research site is in Great Neck, NY.
This study will evaluate an investigational medication for adults with bipolar 1 disorder. To participate, you must be ages 18 to 65, currently experiencing a manic or mixed episode, and willing to be hospitalized. Participants receive study related medication and physical exams at no cost, and compensation for time and travel is available.
The research site is in Arlington, Va.
Copyright 2007 Thomson CenterWatch. All rights reserved.